利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.018 秒)

    FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESULFONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION
    4.
    发明授权
    FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESULFONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION 有权
    丁二酸二异丁酯 - 苯并呋喃半乳糖酸二烯酸二羟甲基纤维素

    公开(公告)号：EP2175859B1

    公开(公告)日：2012-03-07

    申请号：EP08781709.4

    申请日：2008-07-11

    申请人： ChemoCentryx, Inc.

    发明人： KRASINSKI, Antoni ,  PUNNA, Sreenivas ,  UNGASHE, Solomon ,  WANG, Qiang ,  ZENG, Yibin

    IPC分类号： A61K31/519 ,  C07D473/00 ,  C07D487/04 ,  A61P29/00

    CPC分类号： C07D487/04 ,  C07D213/79 ,  C07D213/81 ,  C07D213/84 ,  C07D471/04 ,  C07D471/12 ,  C07D473/00

    摘要： Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2- mediated diseases and as controls in assays for the identification of CCR2 antagonists. A compound of the formula (I) or a salt thereof: where: R1 and R2 are each independently hydrogen, halogen, C1-8alkyl, -CN. or C1-8 haloalkyl, provided that at least one of R11or R2 is other than hydrogen; each R3 is independently hydrogen; R4 is hydrogen; R5 is halogen or C1-8 alkyl; R6 is hydrogen; X1 is CR7, N or NO; X2 and X4 are N or NO; X3 is CR7; X6 and X7 are each independently selected from CR7, N, and NO; each R7 is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C2-8 alkyl, substituted or unsubstituted C2-8 alkeπyl, substituted or unsubstituted C2-8 alkynyl, -CN. =O, -NO2, -OR6, -OC(O)R8, -CO2R8, -C(O)R8, -C(O)NR0R8, -OC(O)NR9R8, -NR10C(O)R8, -NR10C(O)NR9R8, -NR9R8, -NR10CO2R8, -SR8, -S(O)R8, -S(O)2R8, -S(O)2NR9R8, -NR10S(O)2R8, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl;

    摘要翻译： 提供了作为CCR2受体的有效拮抗剂的化合物。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病的方法和用于鉴定CCR2拮抗剂的测定中的对照。